Enveric Biosciences (ENVB) has recently received two patents for its novel psychedelic compounds, which are modeled from psilocybin mushrooms.

Which index performed the best in 2021, the Marijuana Drug Stocks Index, or the Psychedelic Compounds-Based Drug Stocks Index? Which constituents contributed to their performances? This article has the answers.

The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same timeframe.

The psychedelics sector has closed one of its largest M&As since its inception.

The performance of the psychedelic-focused index components substantially outshone the weed stocks.